Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2024-11-14 00:00:00 ET · period of report 2024-11-12 · accession 0001415889-24-026867 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2024-11-14 | 2024-11-12 | SPRY | Tanimoto Sarina | Chief MEDICAL Off, 10% | S - Sale | $16.85 | -100.0K | 1.30M | -7% | -$1.68M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-12 | S | D | 45,045 | $16.76 | 1,301,449 | I By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 | — | — | (F1) The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. (F2) The weighted average sale price for the transaction report was $16.7589, and the range of prices were between $16.405 and $17.395. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. (F3) The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| 2 | Common | Common Stock | 2024-11-12 | S | D | 4,876 | $17.64 | 1,248,499 | I By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 | — | — | (F1) The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. (F7) The weighted average sale price for the transaction reported was $17.6416, and the range of prices were between $17.42 and $17.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. (F6) The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. |
| 3 | Common | Common Stock | 2024-11-12 | S | D | 45,124 | $16.76 | 1,253,375 | I By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006 | — | — | (F1) The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. (F5) The weighted average sale price for the transaction reported was $16.7604, and the range of prices were between $16.40 and $17.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. (F6) The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust. |
| 4 | Common | Common Stock | 2024-11-12 | S | D | 4,955 | $17.64 | 1,296,494 | I By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 | — | — | (F1) The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023. (F4) The weighted average sale price for the transaction reported was $17.643, and the range of prices were between $17.42 and $17.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. (F3) The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |